Literature DB >> 6243919

Human leukocyte interferon: separation of biologically different species by modification of carbohydrate moieties.

M G Salit, C A Ogburn.   

Abstract

Human leukocyte interferon was studied to determine if its antiviral (AV) and growth inhibitory (GI) activities could be separated by enzymatic or chemical cleavage of carbohydrate moieties and electrophoretic procedures. The relative proportion of the two activities (AV:GI ratio) was determined for each gel fraction. Untreated interferon and interferon deglycosylated by glycosidases or metaperiodate were subjected to polyacrylamide gel electrophoresis in sodium dodecyl sulfate. The AV:GI ratio was similar for all fractions, indicating that no dissociation of activities was achieved based on molecular weight differences. The three preparations were then examined by isoelectric focusing to attempt separation based on charge. The untreated sample was resolved into several peaks each with a constant AV:GI ratio of 3:1. Both deglycosylated interferons showed inconstant AV:GI ratios yielding GI fractions that were enriched or depleted in AV activity. These results indicate that under the conditions used the AV and GI activities could not be separated, although molecules can be obtained that differ significantly in their relative antiviral and growth inhibitory properties.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243919     DOI: 10.1007/bf01320770

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  23 in total

1.  Separation of antiviral activity of human interferon from cell growth inhibitory effect.

Authors:  H Dahl; M Degre
Journal:  Nature       Date:  1975-10-30       Impact factor: 49.962

2.  Elimination of size and charge heterogeneities of human leukocyte interferons by chemical cleavage.

Authors:  W E Stewart; L S Lin; M Wiranowska-Stewart; K Cantell
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

3.  Large-scale production of human leukocyte interferon containing 10(8) units per ml.

Authors:  K Cantell; S Hirvonen
Journal:  J Gen Virol       Date:  1978-06       Impact factor: 3.891

4.  Identification of the cell multiplication inhibitory factors in interferon preparations as interferons.

Authors:  W E Stewart; I Gresser; M G Tovey; M Bandu; S Le Goff
Journal:  Nature       Date:  1976-07-22       Impact factor: 49.962

5.  Circulating interferon in rabbits after administration of human interferon by different routes.

Authors:  K Cantell; L Pyhälä
Journal:  J Gen Virol       Date:  1973-07       Impact factor: 3.891

6.  Distribution of antiviral and cell-inhibitory activity in interferon preparations.

Authors:  L Borecký; N Fuchsberger; V Hájnická; D Stancek; J Zemla
Journal:  Acta Virol       Date:  1972-07       Impact factor: 1.162

7.  Inhibition of multiplication of mouse cells in culture by interferon preparations.

Authors:  M Owaki; Y Kawade
Journal:  Acta Virol       Date:  1972-11       Impact factor: 1.162

8.  Production of high-titered interferon in cultures of human diploid cells.

Authors:  E A Havell; J Vilcek
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

9.  Apparent dispensability of the carbohydrate moiety of human interferon for antiviral activity.

Authors:  S Bose; D Gurari-Rotman; U T Ruegg; L Corley; C B Anfinsen
Journal:  J Biol Chem       Date:  1976-03-25       Impact factor: 5.157

10.  Human interferon and cell growth inhibition. II. Biological and physico-chemical properties of the growth inhibitory component.

Authors:  H Dahl
Journal:  Acta Pathol Microbiol Scand B       Date:  1977-02
View more
  2 in total

1.  Enzymatic modifications of human fibroblast and leukocyte interferons.

Authors:  M J Otto; J J Sedmak; S E Grossberg
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

2.  Structure and properties of human interferon-alpha from Namalwa lymphoblastoid cells.

Authors:  G Allen
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.